Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Change in Accured Expenses: 2021-2025

Historic Change in Accured Expenses for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to $746,000.

  • Biofrontera's Change in Accured Expenses fell 29.42% to $746,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 115.22%. This contributed to the annual value of -$230,000 for FY2024, which is 96.38% up from last year.
  • Per Biofrontera's latest filing, its Change in Accured Expenses stood at $746,000 for Q3 2025, which was down 38.70% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Change in Accured Expenses registered a high of $12.4 million during Q3 2021, and its lowest value of -$12.5 million during Q4 2023.
  • For the 3-year period, Biofrontera's Change in Accured Expenses averaged around -$391,909, with its median value being $307,000 (2025).
  • The largest annual percentage gain for Biofrontera's Change in Accured Expenses in the last 5 years was 970.40% (2022), contrasted with its biggest fall of 981.93% (2022).
  • Over the past 5 years, Biofrontera's Change in Accured Expenses (Quarterly) stood at $808,000 in 2021, then tumbled by 981.93% to -$7.1 million in 2022, then crashed by 75.25% to -$12.5 million in 2023, then skyrocketed by 96.84% to -$394,000 in 2024, then declined by 29.42% to $746,000 in 2025.
  • Its last three reported values are $746,000 in Q3 2025, $1.2 million for Q2 2025, and $307,000 during Q1 2025.